Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | MGAM | O43451 | 1/20 | 0.46 |
| ▸ | SI | P14410 | 1/20 | 0.46 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.36 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.35 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.35 |
| ▸ | NLRP3 | Q96P20 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2675052 | 0.83 | GAA (0.43) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL10907242 | 0.83 | ALDH1A1 (0.36) | ALDH1A1TSHRLMNA | |
| SCHEMBL9848230 | 0.82 | GAA (0.41) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL10837934 | 0.80 | GAA (0.48) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL13349132 | 0.78 | GAA (0.46) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL3248904 | 0.77 | GAA (0.50) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL11797072 | 0.77 | GAA (0.44) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL21578793 | 0.76 | GAA (0.48) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL11429024 | 0.76 | GAA (0.48) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL2169435 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324177-B2 | Triterpene compositions and methods for use thereof | RESEARCH DEVELOPMENT FOUNDATION (US) | 2012-12-04 | — | — | US | disclosed |
| US-20110294752-A1 | TRITERPENE COMPOSITIONS AND METHODS FOR USE THEREOF | RESEARCH DEVELOPMENT FOUNDATION (US) | 2011-12-01 | — | — | US | disclosed |
| EP-1079824-B1 | TRITERPENE COMPOSITIONS AND METHODS FOR USE THEREOF | RES DEV FOUNDATION (US) | 2011-08-31 | — | — | EP | disclosed |
| US-7985435-B2 | Triterpene compositions and methods for use thereof | RESEARCH DEVELOPMENT FOUNDATION (US) | 2011-07-26 | — | — | US | disclosed |
| US-20100189824-A1 | TRITERPENE COMPOSITIONS AND METHODS FOR USE THEREOF | ARNTZEN CHARLES J | 2010-07-29 | — | — | US | disclosed |
| US-7670632-B2 | Triterpene compositions and methods for use thereof | RESEARCH DEVELOPMENT FOUNDATION (US) | 2010-03-02 | — | — | US | disclosed |
| EP-1355642-A4 | INHIBITION OF NF-(k)B BY TRITERPENE COMPOSITIONS | RES DEV FOUNDATION (US) | 2007-04-04 | — | — | EP | disclosed |
| US-7105186-B2 | Triterpene compositions and methods for use thereof | RESEARCH DEVELOPMENT FOUNDATION (US) | 2006-09-12 | — | — | US | disclosed |
| US-20060148732-A1 | Inhibition of NF-kappaB by triterpene compositions | RESEARCH DEVELOPMENT FOUNDATION | 2006-07-06 | — | — | US | disclosed |
| US-20060073222-A1 | Triterpene compositions and methods for use thereof | ARNTZEN CHARLES J | 2006-04-06 | — | — | US | disclosed |
| US-20030054052-A1 | Triterpene compositions and methods for use thereof | RESEARCH DEVELOPMENT FOUNDATION | 2003-03-20 | — | — | US | disclosed |
| US-20030039705-A1 | Triterpene compositions and methods for use thereof | RESEARCH DEVELOPMENT FOUNDATION | 2003-02-27 | — | — | US | disclosed |
| US-20030031738-A1 | Triterpene compositions and methods for use thereof | RESEARCH DEVELOPMENT FOUNDATION (US) | 2003-02-13 | — | — | US | disclosed |
| US-6444233-B1 | ANTITUMOR AGENTS | RESEARCH DEVELOPMENT FOUNDATION | 2002-09-03 | — | — | US | disclosed |
| WO-2002055016-A2 | INHIBITION OF NF-λB BY TRITERPENE COMPOSITIONS | RES DEV FOUNDATION (US) | 2002-07-18 | — | — | WO | disclosed |
| US-5728685-A | SELECTIN RECEPTORS FOR INFLAMMATION MODULATORS | GLYCOMED INCORPORATED (US) | 1998-03-17 | — | — | US | disclosed |
| EP-0743951-A4 | SUBSTITUTED LACTOSE DERIVATIVES AS CELL ADHESION INHIBITORS | GLYCOMED INC (US) | 1997-03-19 | — | — | EP | disclosed |
| US-5591835-A | BIND TO RECEPTORS AND MODULATE INFLAMMATION, CANCER, AND RELATED DISEASES BY MODULATING CELL-CELL ADHESION EVENTS | GLYCOMED INCORPORATED (US) | 1997-01-07 | — | — | US | disclosed |
| EP-0743951-A1 | SUBSTITUTED LACTOSE DERIVATIVES AS CELL ADHESION INHIBITORS | GLYCOMED INCORPORATED (US) | 1996-11-27 | — | — | EP | disclosed |
| WO-1995021180-A1 | SUBSTITUTED LACTOSE DERIVATIVES AS CELL ADHESION INHIBITORS | GLYCOMED INCORPORATED (US) | 1995-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294752-A1 | TRITERPENE COMPOSITIONS AND METHODS FOR USE THEREOF | OSTC, ACACA, NFATC1 | GAA 331/4885MGAM 549/4885SI 16/4885 |
| US-20100189824-A1 | TRITERPENE COMPOSITIONS AND METHODS FOR USE THEREOF | OSTC, ACACA, NFATC1 | GAA 331/4885MGAM 549/4885SI 16/4885 |
| US-20030031738-A1 | Triterpene compositions and methods for use thereof | OSTC, ACACA, NFATC1 | GAA 331/4885MGAM 549/4885SI 16/4885 |
| US-20030039705-A1 | Triterpene compositions and methods for use thereof | BAX, CASP3, ACACA | GAA 1798/4885MGAM 2237/4885SI 33/4885 |
| US-20060148732-A1 | Inhibition of NF-kappaB by triterpene compositions | NFKBIA, NFKB2, RELA | GAA 2291/4885MGAM 2515/4885SI 177/4885 |
| US-20060073222-A1 | Triterpene compositions and methods for use thereof | OSTC, ACACA, NFATC1 | GAA 331/4885MGAM 549/4885SI 16/4885 |
| US-20030054052-A1 | Triterpene compositions and methods for use thereof | OSTC, ACACA, NFATC1 | GAA 331/4885MGAM 549/4885SI 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.